ImmunityBio Revenue

In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth. ImmunityBio had revenue of $7.55M in the quarter ending December 31, 2024, with 5,333.09% growth.

Revenue (ttm)

$14.75M

Revenue Growth

+2,270.58%

P/S Ratio

144.24

Revenue / Employee

$21,684

Employees

680

Market Cap

2.53B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	14.75M	14.12M	2,270.58%
Dec 31, 2023	622.00K	382.00K	159.17%
Dec 31, 2022	240.00K	-694.00K	-74.30%
Dec 31, 2021	934.00K	329.00K	54.38%
Dec 31, 2020	605.00K	-1.60M	-72.52%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
UnitedHealth Group	400.28B
Johnson & Johnson	88.82B
Merck & Co.	64.17B
AbbVie	56.33B
AstraZeneca	54.07B
Novartis AG	51.72B
Eli Lilly and Company	45.04B
Thermo Fisher Scientific	42.88B

Revenue Rankings

IBRX News

8 days ago - ImmunityBio to Host Investor Day - Business Wire
21 days ago - ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching - Business Wire
27 days ago - ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum - Seeking Alpha
4 weeks ago - ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024 - Business Wire
4 weeks ago - ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer - Business Wire
6 weeks ago - FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage - Business Wire
6 weeks ago - ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
2 months ago - ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire

More News